NCT06602011View on ClinicalTrials.gov

Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)

RecruitingOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

July 1, 2027

Study Completion Date

October 1, 2028

Conditions
Hepatocellular Carcinoma
Interventions
COMBINATION_PRODUCT

TACE, Lenvatinib, combined with Tislelizumab group

TACE, Lenvatinib \[8mg(\<60kg)/12mg(\>60kg) orally daily\] combination with Tislelizumab (200mg administered intravenous injection on Day 1 of each 21-day cycle). After the triple therapy, surgical resection is an option if assessed by the investigator to be feasible, or continued until disease progression or intolerable if not.

Trial Locations (6)

350005

NOT_YET_RECRUITING

First Affiliated Hospital of Fujian Medical University, Fuzhou

350025

NOT_YET_RECRUITING

Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou

361005

NOT_YET_RECRUITING

Zhongshan Hospital of Xiamen University, Xiamen

361021

NOT_YET_RECRUITING

First Affiliated Hospital of Xiamen University, Xiamen

363099

NOT_YET_RECRUITING

Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou

Unknown

RECRUITING

Fujian Provincial Hospital, Fuzhou

All Listed Sponsors
lead

Fujian Provincial Hospital

OTHER